Neoadjuvant osimertinib for resectable EGFR NSCLC

Stephen V Liu shared on X a recent paper by Collin M. Blakely et al. titled “Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study” published in ASCO Publications.

Authors: Collin M. Blakely, Anatoly Urisman, Matthew A. Gubens, Claire K. Mulvey,  Greg M. Allen, Stephen C. Shiboski, Julia K. Rotow, David M. Jablons et al.   .

“Phase II study of neoadjuvant osimertinib for resectable EGFR NSCLC Journal of Clinical Oncology from Dr. Collin Blakely et al. MPR rate only 14.8% with no pCR observed in 27 pts. Radiographic RR 52%. Osimertinib did not delay or negatively impact surgery.

Not seeing immunotherapy type responses but this will be important work to continue. If we can understand how cancer cells survive and persist, we can develop better strategies to eliminate them (in both early and late stage). Here, TP53 and RBM10 mutations commonly seen.”

Source: Stephen V Liu/X

Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.

As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer.

Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.